Peter Aronstam - Immune Therapeutics CFO

Summary

IMUNDelisted Stock

USD 0.88 0.08 10.00%

CFO

Mr. Peter Aronstam, Ph.D., is Chief Financial Officer of the Company. Mr. Aronstam brings more than 30 years of experience in accounting, finance, banking, international trade and law to his clients. His career is marked by a progression of senior finance roles with growth and performancedriven enterprises, from startup technology and internet companies to chief financial officer roles with small service providers to very large international manufacturers to global banks since 2013.

Age	70
Tenure	11 years
Professional Marks	Ph.D
Phone	888 613 8802
Web	https://www.immunetherapeutics.com

Aronstam has advised publiclyheld and privatelyowned businesses since 1978, providing both fulltime and parttime CFO services. His background includes startup VCbacked entrepreneurial companies, manufacturing technology and service companies, serving as a publiccompany CFO, corporate and international banking in major multinational banks, managing HR and IT functions, and raising more than $500, 000, 000 in debt and equity for his companies and their customers. From 2001 to 2006, Mr. Aronstam was the Chief Financial Officer of Airspan Networks, Inc., a public reporting company in Boca Raton, Florida. He also was the CFO of private company Mainstream Holdings, LLC in West Palm Beach, Florida from 2007 to 2008 and private company The Neptune Society in Plantation, Florida from 2008 to 2009. Since 2010, Mr. Aronstam was a partner of B2B CFO Partners, LLC, doing business as B2B CFO©. The firm provides CFO services to its clients on a part time basis. Born and educated in South Africa, Mr

Immune Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.4526) % which means that it has lost $0.4526 on every $100 spent on assets. This is way below average. Immune Therapeutics' management efficiency ratios could be used to measure how well Immune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Immune Therapeutics to Peers

Immune Therapeutics currently holds 1.08 M in liabilities with Debt to Equity (D/E) ratio of 1.97, which is about average as compared to similar companies. Immune Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immune Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Immune Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immune Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immune to invest in growth at high rates of return. When we think about Immune Therapeutics' use of debt, we should always consider it together with cash and equity.

Immune Therapeutics, Inc. does not have significant operations. Immune Therapeutics, Inc. is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. Immune Therapeutics [IMUN] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Asset

-0.45

Immune Therapeutics Leadership Team

Elected by the shareholders, the Immune Therapeutics' board of directors comprises two types of representatives: Immune Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immune. The board's role is to monitor Immune Therapeutics' management team and ensure that shareholders' interests are well served. Immune Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immune Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.

	Glen MBA, Chief Officer
	Joseph Fortunak, VP of Global RandD and Chemical Devel. and Member of Advisory Board
	Peter Aronstam, CFO
	FMedSci FRACP, Chief RD
	Kelly Wilson, Interim Pres

Immune Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Immune Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Asset	-0.45
	Current Valuation	83.25 M
	Shares Outstanding	82.76 M
	Shares Owned By Insiders	29.51 %
	Price To Earning	333.33 X
	Price To Sales	161.50 X
	Gross Profit	65.83 K
	EBITDA	3.8 M
	Net Income	3.59 M
	Cash And Equivalents	271.53 K

Pair Trading with Immune Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immune Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Immune Pink Sheet

0.55	PBCRY	Bank Central Asia	Pair Corr
0.46	PTAIY	Astra International Tbk	Pair Corr
0.38	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.36	PBCRF	PT Bank Central	Pair Corr

The ability to find closely correlated positions to Immune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immune Therapeutics to buy it.

The correlation of Immune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Immune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Immune Pink Sheet

If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.

	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	CEOs Directory Screen CEOs from public companies around the world
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC